NASDAQ:VLRX - Valeritas Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.48 -0.09 (-5.73 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$1.57
Today's Range$1.44 - $1.58
52-Week Range$1.19 - $7.20
Volume597,936 shs
Average Volume438,960 shs
Market Capitalization$36.05 million
P/E Ratio-0.19
Dividend YieldN/A
Beta4.32
Valeritas logoValeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery. In addition, its products include V-Go Prefill, which is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Receive VLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VLRX
CUSIPN/A
Phone908-927-9920

Debt

Debt-to-Equity Ratio-2.57
Current Ratio2.56
Quick Ratio1.80

Price-To-Earnings

Trailing P/E Ratio-0.19
Forward P/E Ratio-0.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.25 million
Price / Sales1.64
Cash FlowN/A
Price / CashN/A
Book Value($0.59) per share
Price / Book-2.51

Profitability

EPS (Most Recent Fiscal Year)($8.29)
Net Income$-49,300,000.00
Net Margins-225.97%
Return on Equity-1,768.69%
Return on Assets-90.30%

Miscellaneous

Employees103
Outstanding Shares22,390,000

Valeritas (NASDAQ:VLRX) Frequently Asked Questions

What is Valeritas' stock symbol?

Valeritas trades on the NASDAQ under the ticker symbol "VLRX."

How were Valeritas' earnings last quarter?

Valeritas Holdings Inc (NASDAQ:VLRX) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($2.13) by $0.41. The company had revenue of $6.08 million for the quarter, compared to the consensus estimate of $6 million. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 225.97%. View Valeritas' Earnings History.

What price target have analysts set for VLRX?

2 Wall Street analysts have issued twelve-month price targets for Valeritas' stock. Their predictions range from $12.00 to $12.00. On average, they anticipate Valeritas' stock price to reach $12.00 in the next year. View Analyst Ratings for Valeritas.

Who are some of Valeritas' key competitors?

Who are Valeritas' key executives?

Valeritas' management team includes the folowing people:
  • Mr. John E. Timberlake, CEO, Pres & Director (Age 53)
  • Mr. Erick J. Lucera CPA, CFA, CFO & Sec. (Age 50)
  • Mr. Geoffrey H. Jenkins, Exec. VP of Manufacturing, Operations and R&D (Age 66)
  • Dr. Matthew H. Nguyen, Chief Commercial Officer (Age 48)
  • Mr. Mark Conley, VP, Principal Accounting Officer, Corp. Controller & Treasurer (Age 56)

When did Valeritas IPO?

(VLRX) raised $60 million in an initial public offering on Thursday, March 23rd 2017. The company issued 6,000,000 shares at a price of $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow served as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers.

Has Valeritas been receiving favorable news coverage?

News headlines about VLRX stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Valeritas earned a media sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 47.02 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Valeritas?

Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeritas' stock price today?

One share of VLRX stock can currently be purchased for approximately $1.47.

How big of a company is Valeritas?

Valeritas has a market capitalization of $36.05 million and generates $20.25 million in revenue each year. The company earns $-49,300,000.00 in net income (profit) each year or ($8.29) on an earnings per share basis. Valeritas employs 103 workers across the globe.

How can I contact Valeritas?

Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected]


MarketBeat Community Rating for Valeritas (VLRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.